abs

학술발표회초록보기

Inquiry on Abstract abstract@kcsnet.or.kr

Inquiry on Payment member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 03월 02일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

129th General Meeting of Korean Chemical Society & Exposition Hydrotalcite–Niclosamide Nanohybrid as an Anti-SARS-CoV-2 Strategy

Submission Date :
2 / 28 / 2022 , 16 : 59 : 30
Abstract Number :
129022828538
Presenting Type:
Poster Presentation
Presenting Area :
Material Chemistry
Authors :
Seungjin Yu, Huiyan Piao1, Sanoj Rejinold Nirichan1, Yehyun Kim2, Goeun Choi3,*, Jin-Ho Choy4,*
Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 31116, Korea Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dan, Korea
1Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Korea
2Intelligent Nanohybrid Materials Laboratory (INML), Department of Chemistry, Korea
3a. Department of Nanobiomedical Science, b. Institute of Tissue Regeneration Engineering, Korea
4a. Department of Pre-medical Course, b. Institute of Tissue Regeneration Engineering, Korea
Assigned Code :
MAT.P-687 Assigend Code Guideline
Presenting Time :
April 14 (THU) 11:00~13:00
COVID-19 has been affecting millions of individuals worldwide and, thus far, there is no accurate therapeutic strategy. This critical situation necessitates novel formulations for already existing, FDA approved, but poorly absorbable drug candidates, such as niclosamide (NIC), which is of great relevance. In this context, we have rationally designed NIC-loaded hydrotalcite composite nanohybrids, which were further coated with Tween 60 or hydroxypropyl methyl cellulose (HPMC), and characterized them in vitro. The optimized nanohybrids showed particle sizes <300 nm and were orally administrated to rats to determine whether they could retain an optimum plasma therapeutic concentration of NIC that would be effective for treating COVID-19. The pharmacokinetic (PK) results clearly indicated that hydrotalcite-based NIC formulations could be highly potential options for treating the ongoing pandemic and we are on our way to understanding the in vivo anti-viral efficacy sooner. It is worth mentioning that hydrotalcite–NIC nanohybrids maintained a therapeutic NIC level, even above the required IC50 value, after just a single administration in 8-12 h. In conclusion, we were very successfully able to develop a NIC oral formulation by immobilizing with hydrotalcite nanoparticles, which were further coated with Tween 60 or HPMC, in order to enhance their emulsification in the gastrointestinal tract.